Speak to one of our representatives today 0800 0668079 Monday - Friday, 9am - 5pm 
Speak to one of our representatives today 0800 0668079 Monday - Friday, 9am - 5pm
The content of this website has been developed by Napp Pharmaceuticals Limited for healthcare professionals.
Napp is responsible for the content of this website and is also the copyright owner/authorised user of the content.
Please select an option to continue:
Please take me to the Napp healthcare professional website
Reporting adverse events
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Napp Pharmaceuticals Limited at
drugsafetyuk@napp.co.uk.
Please take me to napp.co.uk
Reporting adverse events
If you get any side-effects, talk to your doctor, nurse or pharmacist. This includes any possible side-effects not listed in the package leaflet. You can also report side-effects directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard. By reporting side-effects you can help provide more information on the safety of this medicine.
This webpage contains promotional information regarding Napp products. The content has been reviewed ny Napp to ensure compliance with the ABPI code of practice for the pharmaseutical industry.
About Napp
We’re in the business of bringing medicines to the NHS. It is work that deeply affects the lives of health providers and patients – and here at Napp we pride ourselves on doing it the right way.
The UK is not just our market, it’s our home. We’re a privately owned UK company with a strong track record in bringing high quality, innovative medicines to UK healthcare professionals and their patients.
Please visit us regularly to find the latest information.
Therapy Areas
- Biosimilars
- Cardiovascular
- Diabetes
- Oncology
- Pain Management & Supportive Care
- Respiratory
Important Safety Information
- Long-term use of opioid medicines carries an increased risk of dependence and addiction
- Discuss with patients that prolonged use of opioids may lead to drug dependence and addiction, even at therapeutic doses
- Before starting treatment with opioids, agree with the patient a treatment strategy and plan for end of treatment
- Opioid medicines and benzodiazepines (or benzodiazepine-like drugs) can both cause respiratory depression. When used together, additive effects on the central nervous system increase the risks of sedation, respiratory depression, coma, and death. Only prescribe opioids and benzodiazepines (or benzodiazepine-like drugs) together if there is no alternative
- For further information, please refer to product prescription information and advice for healthcare professionals https://www.gov.uk/drug-safety-update/opioids-risk-of-dependence-and-addiction AND https://www.gov.uk/drug-safety-update/benzodiazepines-and-opioids-reminder-of-risk-of-potentially-fatal-respiratory-depression
Therapy Areas
Important Safety Information
- Long-term use of opioid medicines carries an increased risk of dependence and addiction
- Discuss with patients that prolonged use of opioids may lead to drug dependence and addiction, even at therapeutic doses
- Before starting treatment with opioids, agree with the patient a treatment strategy and plan for end of treatment
- Opioid medicines and benzodiazepines (or benzodiazepine-like drugs) can both cause respiratory depression. When used together, additive effects on the central nervous system increase the risks of sedation, respiratory depression, coma, and death. Only prescribe opioids and benzodiazepines (or benzodiazepine-like drugs) together if there is no alternative
- For further information, please refer to product prescription information and advice for healthcare professionals https://www.gov.uk/drug-safety-update/opioids-risk-of-dependence-and-addiction AND https://www.gov.uk/drug-safety-update/benzodiazepines-and-opioids-reminder-of-risk-of-potentially-fatal-respiratory-depression
Events & Resources
Upcoming Events
- Upcoming Events
- On Demand
- Articles
- Other Resources
Upcoming Events
Therapy Areas: Diabetes
A series of bitesize meetings for HCP’s Managing T2DM: Prioritising Type 2 Diabetes Mellitus
14th Oct
Therapy Areas: Diabetes
A series of bitesize meetings for HCP’s Managing T2DM: Diabetic Kidney Disease in T2DM; the Importance of Identification and Treatment
07th Oct
Therapy Areas: Diabetes
A series of bitesize meetings for HCP’s Managing T2DM: Achieving a Legacy Effect in Type 2 Diabetes Mellitus, Audit and QOF
30th Sep
On Demand
SGLT2is: The New Standard of Care for Diabetic Kidney Disease
T2DM Expert Talks is a series of interviews with national and international experts sharing their best practices and views on diabetes treatment, guidelines and patient care.
In this interview, Dr. Davies will talk about how to identify patients with diabetic kidney disease. She will further expand on the new standard of care, now available, as recommended by international guidelines.
Dr. Sarah Davies
MBBCh (hons), FRCP, MRCGP, PGDip
Clinical Director for Diabetes in Primary Care
for Cardiff and Vale University Health Board
English
00:08:51
Diabetes
webinar
T2DM Expert Talks, Promotional Content
- T2DM Expert Talks, Promotional Content
How to use KDIGO Guidelines for Managing CKD in Type 2 Diabetes
T2DM Expert Talks is a series of interviews with national and international experts sharing their best practices and views on diabetes treatment, guidelines and patient care.
The interview focuses on the key KDIGO recommendations pertinent to the following issues in patients
with T2DM and CKD: glycaemic monitoring and targets, current management and recommendations,
treatment algorithm and approach, evidence on oral SGLT2i based on current UK licence indications.
Dr. David Wheeler, MBChB, MRCP, MD, FRCGP
Professor of Kidney Medicine at University College London and Honorary
Consultant Nephrologist at the Royal Free London NHS Foundation Trust, UK
- English
- 00:06:50
-
Diabetes
- webinar
- T2DM Expert Talks, Promotional Content
- T2DM Expert Talks, Promotional Content
Update on the latest evidence of SGLT2i: A practical guide to their use
The session will provide a clear understanding of the latest evidence for the SGLT2i class, consider the practicalities of their use and their position in the treatment guidelines, as well as exploring and understanding the concept of therapeutic inertia assisting you in improving your type 2 diabetes mellitus patient outcomes.
Professor Melanie Davies,
Professor of Diabetes Medicine,
Leicester Diabetes Centre
SURPASS-1: tirzepatide vs. placebo
Novel dual GIP and GLP-1 receptor agonist tirzepatide as monotherapy in T2DM demonstrated clinically significant reductions in HbA1c and bodyweight without increased risk of clinically significant or severe hypoglycaemia vs placebo in the SURPASS-1 trial.
SURPASS-2: tirzepatide vs. semaglutide
Results from the open-label, randomised SURPASS-2 trial, assessing the novel dual GIP (glucose-dependent insulinotropic polypeptide)/GLP-1 (glucagon-like peptide 1) receptor agonist tirzepatide vs. human GLP-1 receptor agonist semaglutide in 1,878 type 2 diabetes patients inadequately controlled with metformin, conferred statistically significant HbA1c and body weight reductions from baseline compared to semaglutide in all three treatment arms (tirzepatide 5 mg, 10 mg, and 15 mg).
AMPLITUDE-O: efpeglenatide becomes the first long-acting exendin-based GLP-1 receptor agonist to show CV and renal benefits in type 2 diabetes
This cardiovascular outcomes trial evaluated efpeglenatide in 4076 participants with type 2 diabetes and either a history of cardiovascular (CV) disease or current kidney disease plus at least one other cardiovascular risk factor. Participants were randomly assigned 1:1:1 to receive weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg or placebo.
Monthly newsletter
Bringing you the latest publications in type 2 diabetes mellitus selected by our panel of specialists.
